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Whatever "complexity" means, everyone is agreed that biolog- 
ical systems have it. --Physics Today, 1994 
The ABC Transporter/Channel Superfamily 
The ATP-binding cassette (ABC) superfamily is probably 
the largest and most diverse family of proteins that medi- 
ate the selective movement of solutes across biological 
membranes. Many ABC proteins are of considerable clini- 
cal significance: human P-glycoprotein (P-gp) confers re- 
sistance of cancers to chemotherapeutic drugs, Pghl has 
a role in chloroquine resistance of the malarial parasite, 
SUR is the receptor for sulphonylureas used to treat diabe- 
tes and is mutated in patients with persistent hyperinsuli- 
nemic hypoglycemia of infancy, and genes encoding ABC 
transporters are mutated in inherited syndromes such as 
adrenoleukodystrophy, Zellweger syndrome, and cystic 
fibrosis. Thus, the molecular mechanisms by which ABC 
transporters operate, and their physiological roles, are of 
more than passing academic interest. 
Over 100 ABC transporters have been identified in spe- 
cies ranging from Escherichia coil to human (Higgins, 
1992). Each is specific for a single substrate or group of 
related substrates that can range from inorganic ions to 
sugars and amino acids, complex polysaccharides and 
proteins. All ABC transporters hare a common domain 
organization with four "core" domains that may be ex- 
pressed as separate polypeptides or can be fused together 
into larger, multidomain proteins (Figure 1). Two trans- 
membrane domains span the membrane multiple times 
to form the pathway through which solute crosses the 
membrane and determine the substrate specificity/selec- 
tivity of the transporter. Two ATP-binding domains, Io- 
cated at the cytosolic face of the membrane, couple ATP 
hydrolysis to solute movement. These latter domains share 
30%-40% sequence identity with the equivalent domains 
from other ABC transporters, irrespective of their sub- 
strate specificity or species of origin, readily distinguishing 
these ATP-binding cassettes from other nucleotide- 
binding proteins. 
Despite many elegant genetic and biochemical studies, 
we are still some way from understanding the molecular 
mechanisms by which ABC transporters mediate trans- 
membrane translocation of solute. This is, principally, be- 
cause of a lack of structural information. The vast majority 
of ABC proteins are active transporters, utilizing the en- 
ergy of ATP hydrolysis to pump solute across the mem- 
brane. However, the finding that one apparently typical 
ABC transporter, the cystic fibrosis gene product CFTR 
(for cystic fibrosis transmembrane conductance regulator), 
is an ion channel has challenged conventional views on 
the distinction between channels and transporters. It is 
not known whether any other ABC proteins are channels 
rather than transporters. However, over the past year, it 
has emerged that several ABC proteins regulate heterolo- 
gous channels, and perhaps other membrane proteins, 
besides possessing their own intrinsic transporter/channel 
activities. 
ABC Transporters as Channel Regulators 
The Multidrug Resistance P.gp 
The human multidrug resistance P-gp is an active trans- 
porter that utilizes the energy of ATP hydrolysis to pump 
hydrophobic compounds (including chemotherapeutic 
drugs) out of cells. Expression of P-gp in several cell types 
also increases the magnitude of cell swelling-activated CI- 
currents (Valverde et al., 1992; Gill et al., 1992). Although 
the simplest interpretation of the initial data was that P-gp 
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Figure 1. Domain Organization of ABC Transporters 
The four core domains are colored, the transmembrane domains  
blue and the ATP-binding domains in yellow. In some transporters, 
the four core domains are expressed as separate polypeptides ( .g., 
the oligopeptide permease of S. typhimurium). In others, the domains 
can be fused in a variety of configurations. For example, the two ATP- 
binding domains are fused into a single polypeptide in the ribose trans- 
porter of E. coil, and the two transmembrane domains are fused in 
the Fe-hydroxamate ransporter of E. coll. The mammalian TAP1- 
TAP2 peptide transporter, associated with major histocompatibility 
complex (MHC) class I antigen presentation, is a complex of two poly- 
peptides, each comprising a transmembrane domain fused to an ATP- 
binding domain. The human multidrug resistance P-gp and the cystic 
fibrosis gene product CFTR have all four domains fused into a single 
multidomain polypeptide. In some transporters, one polypeptide is
present as a homodimer inthe transport complex to provide the full 
complement of four domains (e.g., HisP in the histidine permease of 
S. typhimurium). Certain ABC transporters include "extra" domains 
(illustrated inwhite), such as the periplasmic binding proteins of bacte- 
rial uptake systems or the regulatory R domain of CFTR, which provide 
specific, additional functions required by individual transporters. For 
references and further details, see Higgins (1992). Figure courtesy of 
R. Bastos (Well-Tempered Software). 
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might itself possess intrinsic channel activity, subsequent 
studies have shown that P-gp is not a channel but that it 
regulates an endogenous channel protein (Luckie et al., 
1994; Hardy et al., 1995). P-gp alters the sensitivity of 
channel activation to osmotic gradients and can impose 
protein kinase C dependency on channel activation. The 
identity of the swelling-activated channel protein is not 
known, although it appears to have a central role in cell 
volume control. Expression of the related ABC protein 
MRP, which also confers drug resistance on cells, also 
alters CI- and K ÷ currents in some cell types (Jirsch et al., 
1993). 
CFTR 
The cystic fibrosis gene product CFTR, besides being a 
CI- channel itself, regulates the activity of several other 
ion channels, and this regulation may be important in the 
pathophysiology of cystic fibrosis. First, an outwardly recti- 
fying CI- channel (ORCC) is abnormally regulated in cystic 
fibrosis cells. It was once suspected that the ORCC might 
be encoded by the cystic fibrosis gene, although it is now 
clear that the ORCC and CFTR are distinct channel pro- 
teins. Expression of CFTR imposes protein kinase A regu- 
lation on the ORCC, and this regulation can be mimicked 
in reconstituted systems (Egan et al., 1993; Gabriel et al., 
1993; Schwiebert et al., 1995; Jovov et al., 1995). Second, 
it has long been known that Na + absorption is increased 
in the airways of cystic fibrosis patients. This cannot be 
a simple indirect electrochemical response to altered CI- 
secretion; instead, the activity of the Na ÷ channel (ENaC) 
itself appears to be altered (Chinet et al., 1994). Third, a 
Ca2+-activated CI- channel is up-regulated in many cystic 
fibrosis cells (Grubb et al., 1994). Transfection of cystic 
fibrosis cells with CFTR restores to normal the activities 
of both this Ca2+-activated CI- channel and the Na + channel 
(Johnson et al., 1995, Stutts et al., 1995). 
Malarial pfmdrl 
The Pghl protein of Plasmodium falciparum, encoded by 
the pfmdrl gene, contributes to antimalarial drug resis- 
tance. Pghl facilitates accumulation of chloroquine in the 
digestive vacuole: pfmdrl mutants show reduced accumu- 
lation and, hence, chloroquine resistance. Although anal- 
ogy with human P-gp would suggest that Pghl is a chlo- 
roquine transporter, chloroquine resistance is a complex 
phenotype, pfmdrl mutations increase vacuolar pH, and 
expression of wild-type (but not mutant) Pghl in CHO cells 
acidifies the lysosomes (van Es et al., 1994). These 
changes in pH may contribute to reduced accumulation 
of weak bases such as chloroquine and hence to drug 
resistance. Intriguingly, human P-gp also acidifies the cy- 
toplasm, and this might contribute to the reduced accumu- 
lation of some drugs (Roepe et al., 1994). There is no 
evidence that Pghl and P-gp are proton pumps, and their 
effects on pH seem to be independent of drug accumula- 
tion. It seems plausible that Pghl (and possibly also P-gp) 
alter [H+]ATPase activity (van Es et al., 1994). 
Bacterial Systems 
As is often the case, the power of bacterial genetics has 
provided the cleanest demonstration that an ARC trans- 
porter also acts as a channel regulator. The sapABCDF 
genes of Salmonella typhimurium encode an ABC trans- 
porter that confers resistance to toxic peptides produced 
by epithelial cells (e.g., defensins), probably by trans- 
porting them into the cytoplasm where they are degraded 
or detoxified (Parra-Lopez et al., 1993). Two additional 
gene products are also required for resistance to these 
toxic peptides, SapG and SapJ. Unexpectedly, the sa- 
pABCDF, sapG, and sapJ loci were found to be true homo- 
logs of the trkE, trkA, and trkH loci of E. coil, respectively, 
which are required for Trk K ÷ channel activity (Parra-Lopez 
et al., 1994). TrkH (SapJ) is a membrane-spanning protein 
believed to form the K ÷ channel pore, while the cyto- 
plasmic NADH-binding protein TrkA (SapG) and the TrkE 
(SapABCDF) ABC transporter are regulators of this chan- 
nel. The peptide transporter and K ÷ channel activities are 
independent and separable processes (Aspedon et al., 
1995, Am. Soc. Microbiol., abstract). The ami locus of 
Streptococcus may also encode an ABC transporter that 
modulates ion transport activities, ami mutations were 
originally isolated by their abilty to confer resistance to 
aminopterins, methotrexate, and other cytotoxics, yet the 
ami locus encodes an ABC transporter that does not ap- 
pear to transport these compounds but is specific for 
peptides (AIIoing et al., 1990). Instead, ami mutants ex- 
hibit altered membrane potential that, indirectly, leads 
to decreased methotrexate and aminopterin sensitivity 
(Trombe, 1993). 
The Sulphonylurea Receptor SUR 
Another intriguing example of considerable clinical signifi- 
cance is emerging from studies of the ATP-sensitive K ÷ 
channel (KATP). Blockade of this channel with sulphonylur- 
eas in pancreatic 13 cells modulates insulin release. In an 
effort to clone the gene encoding KATP, the gene encod- 
ing the sulphonylurea-binding protein (SUR) has recently 
been isolated (Aguilar-Bryan et al., 1995). Mutations in 
this gene are associated with persistent hyperinsulinemic 
hypoglycemia of infancy (Thomas et al., 1995). However, 
SUR is an ABC transporter and does not appear to be 
the channel itself. Instead, it seems probable ~that SUR 
imposes sulphonylurea sensitivity on another protein that 
forms the channel. The precise identity of the channel 
protein is not yet known. Although a candidate, I~Tp, has 
been proposed (Ashford et al., 1994), IKATP (also called 
cardiac inward rectifier [CIR]) forms a heteromultimer with 
the GIRK1 channel to generate the G protein-gated atrial 
K ÷ channel IKAch, complicating any analysis (Krapivinsky 
et al., 1995). 
Mechanisms of Regulation 
How do ABC transporters regulate the activity of heterolo- 
gous channels? Is there a single mechanism, or do differ- 
ent ABC transporters act by different mechanisms? Al- 
though we have few answers, a number of clues are 
emerging. 
The possibility that regulation is at the level of gene 
expression, rather than channel activity, can be excluded 
for several of the systems described here. For example, 
CFTR alters Na + channel activity but does not alter the 
amount of Na ÷ channel expressed in the cell (Stutts et al., 
1995); the ORCC is present in membranes of non-CFTR- 
expressing cells but can only be activated normally when 
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CFTR is present (Egan et al., 1993; Gabriel et al., 1993); 
P-gp regulates the threshold osmolarity at which cell swell- 
ing-regulated CI- channels are activated, rather than the 
maximum magnitude of channel activity (Luckie et al., 
1994; Hardy et al., 1995). 
The most straightforward mechanism by which an ABC 
transporter might regulate a heterologous channel is by 
transporting a regulatory molecule (Figure 2A): in this 
model, regulation is a secondary consequence of the nor- 
mal transporter/channel activity of the ABC protein and 
does not require that the protein is truly bifunctional. Al- 
though some ABC transporters doubtless transport egu- 
latory molecules, most, if not all, of the effects described 
here are not mediated by this mechanism. For example, 
a mutation in the ATP-binding domain of the multidrug 
resistance P-gp transporter reduces transport activity to 
an undetectable level yet does not prevent P-gp acting as 
a channel regulator (Gill et al., 1992). A recent intriguing 
report shows that CFTR increases ATP efflux from cells 
and that this ATP interacts with extracellular eceptors to 
activate the ORCC (Schwiebert et al., 1995). This, poten- 
tially, provides insight into a mechanism of heterologous 
channel regulation. It remains to be tested whether ATP 
release is mediated via the intrinsic CI- channel activity 
of CFTR itself or via a heterologous pathway that is acti- 
vated by CFTR, independently of its CI- channel activity. 
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Figure 2. Mechanisms by Which ABC Transporters Might Regulate 
Channel Activity 
The four core domains of the ABC transporter are illustrated in red 
(transmembrane domains) and yellow (ATP-binding domains). The 
regulated channel is shown in green. 
(A) A substrate (X) transported by the ABC protein acts as a regulatory 
molecule to modulate channel activity. 
(B) The ABC transporter increases insertion of channel proteins into 
the membrane. 
(C) The ABC transporter interacts directly with t e channel protein to 
modulate its activity. 
(D) The ABC transporter interacts with the channel protein through 
intermediate protein molecules (blue), possibly cytoskeletal compo- 
nents. 
If, then, we assume that he regulation of heterologous 
proteins by ABC transporters is distinct from their intrinsic 
channel/transporter activity, many direct and indirect 
mechanisms can be envisaged (Figure 2). These are not 
mutually exclusive, and many variations can be enter- 
tained. However, they all require that the ABC transporters 
are truly bifunctional, with a regulatory activity distinct from 
and additional to any intrinsic transporter/channel activity. 
Among the indirect mechanisms is vesicle trafficking 
(Figure 2B), in which the ABC protein facilitates insertion 
of additional channel proteins into the membrane. CFTR 
has been reported to influence vesicle trafficking in some 
cells (Bradbury et al., 1992), and this may be important 
in specific circumstances. However, membrane insertion 
cannot account for all of the regulatory effects described 
here: CFTR regulates ORCC activity in isolated mem- 
brane patches where trafficking cannot apply, and, of 
course, membrane trafficking does not occur in prokary- 
otic cells. Another indirect mechanism, although perhaps 
unlikely, is through altered membrane lipid composition 
or organization. Many transporters and channels are sen- 
sitive to the nature of membrane lipids, and at least one 
ABC transporter, the MDR2 gene product, is known to 
transport phospholipids (Reutz and Gros, 1994). Such a 
mechanism would, however, lack specificity. 
Direct protein-protein interactions eem, at least to this 
author, the most likely mechanism by which ABC trans- 
porters might regulate heterologous proteins. There is little 
direct evidence either for or against this hypothesis, al- 
though a recent study provides an indication that CFTR 
may regulate ENaC (the Na-- channel) via protein-protein 
interactions (Stutts et al., 1995). Most simply, the ABC 
protein would form a complex with heterologous channel 
proteins in the membrane (Figure 2C). This could generate 
specificity of regulation and is realistic for both prokaryotic 
and eukaryotic systems. Alternatively, interactions might 
involve intermediate proteins, such as cytoskeletal com- 
ponents (Figure 2D). There is a precedent in the erythro- 
cyte membrane for cross-talk between membrane proteins 
via the cytoskeleton: the band 3 anion exchanger Na÷/ 
K÷-ATPase and the glucose transporter influence each 
other's activities through interactions with ankyrin and 
spectrin (Mills et al., 1994). 
Physiological and Clinical Significance 
The effects of ABC transporters on the activity of heterolo- 
gous channels and other proteins have generally been 
observed in perturbed systems, either after heterologous 
overexpression or in mutants and transgenic mouse mod- 
els. It can, therefore, reasonably be asked: do these regu- 
latory effects reflect functional interactions that occur in 
normal cells, or are they a fortuitous consequence of ex- 
perimental perturbations? Although there is little direct evi- 
dence that these regulatory phenomena are relevant to 
normal cells, a compelling case is provided by the increas- 
ing body of indirect evidence. Furthermore, even if these 
regulatory interactions are not relevant in normal cells, 
there is no doubt that several are of real significance in 
diseased states (e.g., cystic fibrosis and multidrug resis- 
tance) and so deserve serious attention. 
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Why do such regulatory interactions occur? If regulation 
by ABC transporters is of real physiological relevance, the 
transporter must impose novel responses on the channel. 
This is seen for P-gp and CFTR, which appear to impose 
regulation by protein kinases on associated channels. 
Some ABC transporters may confer regulation by small 
molecules. For example, SU R is believed to confer sulpho- 
nylurea sensitivity on the KATP channel, possibly mimicking 
an endogenous regulatory sulphonylurea. Cytotoxic drugs 
can also modify the ability of P-gp to modulate cell swell- 
ing-activated CI- channels (Gill et al., 1992), possibly re- 
flecting regulation by an unknown endogenous molecule. 
As ABC transporters pan the cell membrane, extracellu- 
lar regulatory molecules may also be sensed. A precedent 
for transmembrane signal transduction by an ABC trans- 
porter is provided by the PstSCAB phosphate transporter 
of E. coll. Together with the cytoplasmic PhoU protein, 
PstSCAB is required for the repression of many E. coil 
genes by extracellular phosphate (Steed and Wanner, 
1993). Phosphate transport is not necessary for this re- 
pression, implying that the ABC transporter transduces a 
signal across the membrane to modulate PhoU activity 
and, hence, gene expression. The interaction of the malt- 
ose-binding protein with the E. coil maltose ABC trans- 
porter at the extracellular face of the membrane also initi- 
ates a signal, presumed to be a conformational change, 
that is transmitted across the membrane to the ATP- 
binding domains (Davidson et al., 1992). Intriguingly, the 
ATP-binding domains of ABC transporters resemble Ras 
and other G proteins, and a conformational change in 
these domains could have regulatory consequences for 
proteins with which they interact. Although, in these bacte- 
rial examples, channel regulation is not involved, this 
transduction mechanism could equally be applied to a 
channel or any other interacting protein. 
Concluding Comments 
There is rapidly emerging evidence that a number of ABC 
transporters are bifunctional, regulating channel activity 
independently of their normal transporter/channel activity. 
In some cases, ABC transporters may regulate mem- 
brane-associated proteins other than channels. It is not 
known what proportion of ABC transporters have these 
regulatory functions. These regulatory events have con- 
siderable physiological consequences, at least in certain 
disease states. Furthermore, the finding that channel ac- 
tivities can be modulated by other membrane proteins, 
perhaps by direct interactions, may account for the diffi- 
culties in isolating some channels and their genes. Eluci- 
dating the mechanisms of these regulatory phenomena 
is essential if we are to integrate the functions of individual 
ABC transporters and channels into cell physiology and to 
understand the complex system that is the cell membrane. 
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